GLUE
NASDAQStockMonte Rosa Therapeutics, Inc.
$16.03-0.01 (-0.06%)
52-Week Range
$3.70
$25.31
Key Stats
Market Cap
1.0B
P/E Ratio
—
Dividend Yield
—
Beta
1.64
Volume
596.5K
Avg Volume
956.9K
Performance
1M
-10.49%
3M
-2.49%
6M
+147.91%
YTD
+4.77%
1Y
+138.34%
3Y
+128.82%
5Y
-24.27%
Price Chart
ETF Exposure
GLUE is held by 93 ETFs
| ETF | Fund Name | Weight |
|---|---|---|
| FHLC | FIDELITY MSCI HEALTH CARE INDEX ETF | 0.01% |
| CUS1.L | iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETF | 0.01% |
| CUSS.L | iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETF | 0.01% |
| SXRG.DE | iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETF | 0.01% |
| IUSN.DE | iShares MSCI World Small Cap UCITS ETF | 0.01% |
| SMMD | iShares Russell 2500 ETF | 0.01% |
| WSML.L | iShares MSCI World Small Cap UCITS ETF | 0.01% |
| WSML | iShares MSCI World Small-Cap ETF | 0.01% |
| HDG | ProShares - Hedge Replication ETF | 0.00% |
| ONEQ | FIDELITY NASDAQ COMPOSITE INDEX ETF | 0.00% |
| AVUS | Avantis U.S. Equity ETF | 0.00% |
| DCOR | Dimensional - US Core Equity 1 ETF | 0.00% |
| DFAC | Dimensional - US Core Equity 2 ETF | 0.00% |
| DFAU | Dimensional - US Core Equity Market ETF | 0.00% |
| ITOT | iShares Core S&P Total U.S. Stock Market ETF | 0.00% |
| SCHB | Schwab U.S. Broad Market ETF | 0.00% |
| USFM.L | UBS MSCI USA Select Factor Mix UCITS ETF USD dis | 0.00% |
| VTI | Vanguard Total Stock Market ETF | 0.00% |
| VUN.TO | Vanguard U.S. Total Market Index ETF | 0.00% |
| VUS.TO | Vanguard U.S. Total Market Index ETF (CAD-hedged) | 0.00% |
| AVUQ | Avantis U.S. Quality ETF | 0.00% |
| DFUS | Dimensional - US Equity Market ETF | 0.00% |
| IWV | iShares Russell 3000 ETF | 0.00% |
| VEQT.TO | Vanguard All-Equity ETF Portfolio | 0.00% |
| VTHR | Vanguard Russell 3000 ETF | 0.00% |
| XEQT.TO | iShares Core Equity ETF Portfolio | 0.00% |
| XUU.TO | iShares Core S&P U.S. Total Market Index ETF | 0.00% |
| ITDB | iShares LifePath Target Date 2030 ETF | 0.00% |
| ITDC | iShares LifePath Target Date 2035 ETF | 0.00% |
| ITDD | iShares LifePath Target Date 2040 ETF | 0.00% |
| ITDE | iShares LifePath Target Date 2045 ETF | 0.00% |
| ITDF | iShares LifePath Target Date 2050 ETF | 0.00% |
| ITDG | iShares LifePath Target Date 2055 ETF | 0.00% |
| ITDH | iShares LifePath Target Date 2060 ETF | 0.00% |
| ITDI | iShares LifePath Target Date 2065 ETF | 0.00% |
| ITDJ | iShares LifePath Target Date 2070 ETF | 0.00% |
| LSLT | Pacer Salt Low truBeta US Market ETF | 0.00% |
| SLT | Pacer Salt High truBeta US Market ETF | 0.00% |
| TRPL | Pacer Metaurus US Large Cap Dividend Multiplier 300 ETF | 0.00% |
| VCNS.TO | Vanguard Conservative ETF Portfolio | 0.00% |
| VETS | Pacer Military Times Best Employers ETF | 0.00% |
| VIRS | Pacer BioThreat Strategy ETF | 0.00% |
| VRIF.TO | Vanguard Retirement Income ETF Portfolio | 0.00% |
PreviousPage 2 of 2
About GLUE ETF Exposure
Monte Rosa Therapeutics, Inc. (GLUE) is held by 93 exchange-traded funds, making it one of the stocks with significant ETF exposure. With a market capitalization of 1.0B, GLUE is a widely held institutional stock. The stock currently trades at $16.03. Investors can gain exposure to GLUE through a variety of ETFs with different expense ratios, investment strategies, and portfolio weightings. The table above shows all ETFs that currently hold GLUE, sorted by portfolio weight.